top of page
The Sound of Evolution
Golimumab
Mechanism of action:
Golimumab is a monoclonal antibody that specifically targets tumor necrosis factor-α (TNF-α). Golimumab binds to both soluble and membrane-bound TNF-α, preventing TNF-α from binding to its cell surface receptors, TNFR1 and TNFR2. This suppresses downstream TNF-α-mediated inflammatory signaling and reduces the induced expression of pro-inflammatory cytokines such as IL-1 and IL-6, as well as chemokines and adhesion molecules.
Reference(s):
1. Oldfield V et al. (2009). Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrugs.
2. Sandborn WJ et al. (2014). Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology.
bottom of page